Ghost Tree Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Ghost Tree Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-80,000	Closed	-$14.7M	–	50
2019 Q1	$14.7M	Hold	80,000	–	–	3.84%	8
2018 Q4	$13.3M	Buy	+80,000	New	+$13.9M	4.81%	4
2017 Q4	–	Sell	-50,000	Closed	-$7.6M	–	68
2017 Q3	$7.6M	Buy	+50,000	New	+$7.53M	1.61%	24
2017 Q2	–	Sell	-90,000	Closed	-$9.84M	–	77
2017 Q1	$9.84M	Buy	+90,000	New	+$7.92M	1.83%	17
2016 Q2	–	Sell	-25,253	Closed	-$2.01M	–	80
2016 Q1	$2.01M	Buy	+25,253	New	+$2.28M	1.14%	31
2015 Q3	–	Sell	-60,000	Closed	-$7.41M	–	93
2015 Q2	$7.41M	Buy	+60,000	New	+$7.56M	2.4%	12
2014 Q4	–	Sell	-40,000	Closed	-$4.49M	–	82
2014 Q3	$4.49M	Buy	+40,000	New	+$3.81M	2.44%	9

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ghost Tree Capital's VRTX Position: Q2 2019 in Review

Ghost Tree Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2019, closing a stake of 80,000 shares — an estimated $14.7M sold.

Ghost Tree Capital first reported a position in VRTX in Q3 2014 and held it in 7 quarters. The position peaked at $14.7M in Q1 2019. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Ghost Tree Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Ghost Tree Capital sold 80,000 Vertex Pharmaceuticals shares in Q2 2019, an estimated $14.7M.
Ghost Tree Capital first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 7 quarters.
Ghost Tree Capital's Vertex Pharmaceuticals position peaked at $14.7M in Q1 2019.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Ghost Tree Capital's 13F filing for Q2 2019, filed 14 Aug 2019.